BCRX logo

BioCryst Pharmaceuticals, Inc. (BCRX) Cash and Cash Equivalents

Annual Cash & Cash Equivalents:

$104.71M-$5.93M(-5.36%)
December 31, 2024

Summary

  • As of today, BCRX annual cash & cash equivalents is $104.71 million, with the most recent change of -$5.93 million (-5.36%) on December 31, 2024.
  • During the last 3 years, BCRX annual cash & cash equivalents has fallen by -$399.68 million (-79.24%).
  • BCRX annual cash & cash equivalents is now -79.24% below its all-time high of $504.39 million, reached on December 31, 2021.

Performance

BCRX Cash and Cash Equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherBCRXbalance sheet metrics

Quarterly Cash & Cash Equivalents:

$213.45M-$47.08M(-18.07%)
September 30, 2025

Summary

  • As of today, BCRX quarterly cash & cash equivalents is $213.45 million, with the most recent change of -$47.08 million (-18.07%) on September 30, 2025.
  • Over the past year, BCRX quarterly cash & cash equivalents has dropped by -$117.37 million (-35.48%).
  • BCRX quarterly cash & cash equivalents is now -58.22% below its all-time high of $510.95 million, reached on December 31, 2021.

Performance

BCRX Quarterly Cash & Cash Equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherBCRXbalance sheet metrics

Cash and Cash Equivalents Formula

Cash & Cash Equivalents = Cash + Short-Term Investments

BCRX Cash and Cash Equivalents Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1Y1 Year-5.4%-35.5%
3Y3 Years-79.2%-50.2%
5Y5 Years-8.3%+46.7%

BCRX Cash and Cash Equivalents Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs Low
3Y3-Year-79.2%at low-50.2%at low
5Y5-Year-79.2%at low-58.2%+46.7%
All-TimeAll-Time-79.2%+3778.3%-58.2%>+9999.0%

BCRX Cash and Cash Equivalents History

DateAnnualQuarterly
Sep 2025
-
$213.45M(-18.1%)
Jun 2025
-
$260.53M(-11.8%)
Mar 2025
-
$295.38M(-8.0%)
Dec 2024
$104.71M(-5.4%)
$321.06M(-3.0%)
Sep 2024
-
$330.83M(+20.8%)
Jun 2024
-
$273.82M(-19.1%)
Mar 2024
-
$338.35M(-13.4%)
Dec 2023
$110.64M(-63.7%)
$390.79M(-2.1%)
Sep 2023
-
$399.17M(-3.2%)
Jun 2023
-
$412.24M(+3.2%)
Mar 2023
-
$399.62M(-6.1%)
Dec 2022
$304.77M(-39.6%)
$425.78M(-0.6%)
Sep 2022
-
$428.30M(+2.2%)
Jun 2022
-
$418.93M(-6.2%)
Mar 2022
-
$446.82M(-12.6%)
Dec 2021
$504.39M(+85.4%)
$510.95M(+150.6%)
Sep 2021
-
$203.89M(-8.5%)
Jun 2021
-
$222.78M(-8.8%)
Mar 2021
-
$244.36M(-19.2%)
Dec 2020
$272.13M(+138.3%)
$302.59M(+107.9%)
Sep 2020
-
$145.53M(-24.0%)
Jun 2020
-
$191.59M(+67.2%)
Mar 2020
-
$114.62M(-16.8%)
Dec 2019
$114.17M(+327.1%)
$137.78M(+96.9%)
Sep 2019
-
$69.98M(-27.7%)
Jun 2019
-
$96.78M(-12.0%)
Mar 2019
-
$109.95M(+3.7%)
Dec 2018
$26.73M(-46.8%)
$106.01M(-13.0%)
Sep 2018
-
$121.83M(+37.9%)
Jun 2018
-
$88.36M(-7.9%)
Mar 2018
-
$95.91M(-18.5%)
Dec 2017
$50.28M(+127.5%)
$117.68M(-28.6%)
Sep 2017
-
$164.75M(+91.5%)
Jun 2017
-
$86.03M(-15.2%)
Mar 2017
-
$101.48M(+80.6%)
Dec 2016
$22.10M(-23.5%)
$56.20M(+3.4%)
Sep 2016
-
$54.33M(+35.3%)
Jun 2016
-
$40.17M(+6.3%)
Mar 2016
-
$37.78M(-47.5%)
Dec 2015
$28.90M(-47.0%)
-
Sep 2015
-
$71.95M(-25.0%)
Jun 2015
-
$95.93M(+36.7%)
Mar 2015
-
$70.16M(-3.8%)
Dec 2014
$54.54M(+157.7%)
$72.92M(-42.7%)
Sep 2014
-
$127.28M(-3.8%)
Jun 2014
-
$132.26M(+319.3%)
Mar 2014
-
$31.54M(-17.4%)
Dec 2013
$21.16M(+1.3%)
$38.21M(-10.6%)
Sep 2013
-
$42.74M(+36.8%)
Jun 2013
-
$31.25M(+8.2%)
Mar 2013
-
$28.88M(-19.6%)
Dec 2012
$20.89M(+27.0%)
$35.91M(-13.1%)
Sep 2012
-
$41.32M(+11.3%)
Jun 2012
-
$37.11M(-16.1%)
Mar 2012
-
$44.23M(+4.5%)
Dec 2011
$16.44M(+20.7%)
$42.34M(-5.1%)
Sep 2011
-
$44.62M(-24.4%)
Jun 2011
-
$59.01M(-14.6%)
Mar 2011
-
$69.10M(+26.6%)
Dec 2010
$13.62M
$54.57M(-11.1%)
Sep 2010
-
$61.39M(+9.3%)
Jun 2010
-
$56.18M(-11.8%)
DateAnnualQuarterly
Mar 2010
-
$63.67M(-8.5%)
Dec 2009
$41.12M(+84.1%)
$69.59M(+96.1%)
Sep 2009
-
$35.48M(-16.0%)
Jun 2009
-
$42.26M(-22.1%)
Mar 2009
-
$54.21M(-11.9%)
Dec 2008
$22.34M(-28.3%)
$61.53M(-4.9%)
Sep 2008
-
$64.68M(+68.4%)
Jun 2008
-
$38.40M(-15.7%)
Mar 2008
-
$45.55M(-10.2%)
Dec 2007
$31.16M(+605.3%)
$50.70M(-26.2%)
Sep 2007
-
$68.71M(+122.6%)
Jun 2007
-
$30.87M(-16.7%)
Mar 2007
-
$37.06M(-1.1%)
Dec 2006
$4.42M(-84.8%)
$37.46M(-14.5%)
Sep 2006
-
$43.81M(-20.0%)
Jun 2006
-
$54.77M(-20.0%)
Mar 2006
-
$68.44M(+36.2%)
Dec 2005
$29.16M(+229.9%)
$50.26M(+63.0%)
Sep 2005
-
$30.84M(-6.7%)
Jun 2005
-
$33.05M(-19.5%)
Mar 2005
-
$41.04M(+77.1%)
Dec 2004
$8.84M(+5.9%)
$23.17M(+1.0%)
Sep 2004
-
$22.95M(-5.0%)
Jun 2004
-
$24.16M(-15.3%)
Mar 2004
-
$28.52M(+42.4%)
Dec 2003
$8.35M(-39.6%)
$20.03M(+3.0%)
Sep 2003
-
$19.45M(-22.5%)
Jun 2003
-
$25.10M(+9.8%)
Mar 2003
-
$22.86M(-6.5%)
Dec 2002
$13.82M(-26.7%)
$24.45M(-10.0%)
Sep 2002
-
$27.16M(+1.1%)
Jun 2002
-
$26.88M(-8.1%)
Mar 2002
-
$29.26M(-8.5%)
Dec 2001
$18.87M(+123.1%)
$31.99M(+3.2%)
Sep 2001
-
$31.01M(-3.4%)
Jun 2001
-
$32.09M(-3.5%)
Mar 2001
-
$33.26M(+35.0%)
Dec 2000
$8.46M(-1.7%)
$24.64M(-3.8%)
Sep 2000
-
$25.61M(-3.1%)
Jun 2000
-
$26.43M(-1.0%)
Mar 2000
-
$26.69M(+43.3%)
Dec 1999
$8.60M(-30.1%)
-
Mar 1999
-
$18.63M(+12.6%)
Dec 1998
$12.30M(+223.7%)
-
Sep 1998
-
$16.54M(-14.2%)
Jun 1998
-
$19.28M(-3.9%)
Mar 1998
-
$20.06M(+427.9%)
Dec 1997
$3.80M(+5.6%)
$3.80M(-32.1%)
Sep 1997
-
$5.60M(+19.1%)
Jun 1997
-
$4.70M(+38.2%)
Mar 1997
-
$3.40M(-5.6%)
Dec 1996
$3.60M(-41.0%)
$3.60M(-44.6%)
Sep 1996
-
$6.50M(+3.2%)
Jun 1996
-
$6.30M(-34.4%)
Mar 1996
-
$9.60M(+57.4%)
Dec 1995
$6.10M(+125.9%)
$6.10M(-53.1%)
Sep 1995
-
$13.00M(-10.3%)
Jun 1995
-
$14.50M(+705.6%)
Mar 1995
-
$1.80M(-33.3%)
Dec 1994
$2.70M
$2.70M(-42.6%)
Sep 1994
-
$4.70M(+46.9%)
Jun 1994
-
$3.20M(-52.2%)
Mar 1994
-
$6.70M

FAQ

  • What is BioCryst Pharmaceuticals, Inc. annual cash & cash equivalents?
  • What is the all-time high annual cash & cash equivalents for BioCryst Pharmaceuticals, Inc.?
  • What is BioCryst Pharmaceuticals, Inc. annual cash & cash equivalents year-on-year change?
  • What is BioCryst Pharmaceuticals, Inc. quarterly cash & cash equivalents?
  • What is the all-time high quarterly cash & cash equivalents for BioCryst Pharmaceuticals, Inc.?
  • What is BioCryst Pharmaceuticals, Inc. quarterly cash & cash equivalents year-on-year change?

What is BioCryst Pharmaceuticals, Inc. annual cash & cash equivalents?

The current annual cash & cash equivalents of BCRX is $104.71M

What is the all-time high annual cash & cash equivalents for BioCryst Pharmaceuticals, Inc.?

BioCryst Pharmaceuticals, Inc. all-time high annual cash & cash equivalents is $504.39M

What is BioCryst Pharmaceuticals, Inc. annual cash & cash equivalents year-on-year change?

Over the past year, BCRX annual cash & cash equivalents has changed by -$5.93M (-5.36%)

What is BioCryst Pharmaceuticals, Inc. quarterly cash & cash equivalents?

The current quarterly cash & cash equivalents of BCRX is $213.45M

What is the all-time high quarterly cash & cash equivalents for BioCryst Pharmaceuticals, Inc.?

BioCryst Pharmaceuticals, Inc. all-time high quarterly cash & cash equivalents is $510.95M

What is BioCryst Pharmaceuticals, Inc. quarterly cash & cash equivalents year-on-year change?

Over the past year, BCRX quarterly cash & cash equivalents has changed by -$117.37M (-35.48%)
On this page